SCHEMBL3363396

SCHEMBL3363396

OC(=S)NCCOc1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 1/20 0.62
MTNR1B P49286 1/20 0.62
RAB9A P51151 6/20 0.61
NPC1 O15118 5/20 0.61
SMN1; SMN2 Q16637 4/20 0.61
HPGD P15428 1/20 0.61
DRD4 P21917 3/20 0.57
HTR1B P28222 2/20 0.57
DRD2 P14416 2/20 0.57
DRD3 P35462 2/20 0.57
HTR1D P28221 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.56
RECQL P46063 3/20 0.53
KCNA3 P22001 1/20 0.52
ALDH1A1 P00352 1/20 0.52
PKM P14618 2/20 0.51
EPHX2 P34913 1/20 0.51
GAA P10253 1/20 0.50
LMNA P02545 1/20 0.50
POLB P06746 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11305595 0.93 MTNR1A (0.56) MTNR1AMTNR1BRAB9ANPC1SMN1; SMN2
SCHEMBL10828204 0.88 L3MBTL1 (0.57) MTNR1AMTNR1BHPGDDRD4HTR1B
SCHEMBL11305922 0.85 MTNR1A (0.47) MTNR1AMTNR1BRAB9ANPC1SMN1; SMN2
SCHEMBL6804590 0.85 MTNR1A (0.59) MTNR1AMTNR1BRAB9ANPC1SMN1; SMN2
SCHEMBL11305403 0.84 GAA (0.62) MTNR1AMTNR1BRAB9ANPC1SMN1; SMN2
SCHEMBL10459746 0.83 MTNR1A (0.62) MTNR1AMTNR1BRAB9ANPC1SMN1; SMN2
SCHEMBL3446802 0.80 MTNR1A (0.73) MTNR1AMTNR1BRAB9ANPC1SMN1; SMN2
SCHEMBL4576541 0.78 MTNR1A (0.65) MTNR1AMTNR1BRAB9ANPC1SMN1; SMN2
SCHEMBL885015 0.77 MTNR1A (1.00) MTNR1AMTNR1BRAB9ANPC1SMN1; SMN2
SCHEMBL10310294 0.77 MTNR1A (0.59) MTNR1AMTNR1BRAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597421-B2 Protected monomer and method of final deprotection for RNA synthesis AGILENT TECHNOLOGIES, INC. (US) 2020-03-24 US disclosed
EP-2331558-B1 PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS AGILENT TECHNOLOGIES INC (US) 2018-09-12 EP disclosed
US-20180186826-A1 PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS AGILENT TECHNOLOGIES, INC. 2018-07-05 US disclosed
US-9273086-B2 Protected monomer and method of final deprotection for RNA synthesis AGILENT TECHNOLOGIES, INC. (US) 2016-03-01 US disclosed
US-20120289691-A1 PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS AGILENT TECHNOLOGIES, INC. (US) 2012-11-15 US disclosed
US-20120184724-A1 PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS AGILENT TECHNOLOGIES, INC. (US) 2012-07-19 US disclosed
US-20100076183-A1 PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS AGILENT TECHNOLOGIES, INC. 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289691-A1 PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS NSUN2, SNRPB2, RNGTT MTNR1A 2836/4885MTNR1B 2786/4885RAB9A 4861/4885
US-20180186826-A1 PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS NSUN2, RNGTT, RNMT MTNR1A 3562/4885MTNR1B 3606/4885RAB9A 4405/4885
US-20100076183-A1 PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS RNGTT, RNMT, NSUN2 MTNR1A 2765/4885MTNR1B 1856/4885RAB9A 4700/4885
US-10597421-B2 Protected monomer and method of final deprotection for RNA synthesis NSUN2, RNGTT, RNMT MTNR1A 3562/4885MTNR1B 3606/4885RAB9A 4405/4885
US-20120184724-A1 PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS RNMT, RNGTT, NSUN2 MTNR1A 1721/4885MTNR1B 1212/4885RAB9A 4258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.